N-methyl-d-aspartate antagonists in levodopa induced dyskinesia: A meta-analysis

Canadian Journal of Neurological Sciences

Volumn 39, Issue 4, 2012, Pages 465-472

  Elahi, Behzad ^a   Phielipp, Nicolás ^a   Chen, Robert ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; DEXTROMETHORPHAN; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; QUINIDINE; REMACEMIDE;

ARTICLE; DRUG EFFICACY; DYSKINESIA; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; TREATMENT OUTCOME;

EID: 84863325453     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100013974     Document Type: Article

References (37)

1. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990 Dec 7;250(4986): 1429-32.
2. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology. 1998;50(5 Suppl 5): S17-S25.
3. Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis. 2003;14(3):404-16.
4. Nash JE, Fox SH, Henry B, et al. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol. 2000;165(1):136-42.
5. Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11;66(7):983-95.
6. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol. 2006 Nov;13(11):1186-202.
7. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol. 2009 Jan;8(1):67-81.
8. Wagle-Shukla A, Angel MJ, Zadikoff C, et al. Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias. Neurology. 2007 Feb 27;68(9): 704-5.
9. Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther. 2010 Jun;333(3):865-73.
10. Morissette M, Dridi M, Calon F, et al. Prevention of levodopainduced dyskinesias by a selective NR1A/2B N-methyl-Daspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord. 2006 Jan;21(1): 9-17.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4.
12. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA. 1994 Jan 5;271(1):59-63.
13. Higgins JPT e, Green S e. Cochrane Handbook for Systematic Reviews of interventions, http://www.cochrane.org/resources/handbook/hbook.htm; September 2008.
14. Verhagen ML, Blanchet PJ, van den MP, Del Dotto P, Natte R, Chase TN. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord. 1998;13(3): 414-7.
15. Verhagen ML, Del Dotto P, Natte R, van den MP, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology. 1998;51(1):203-6.
16. Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol. 2001;58(10):1660-8.
17. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a doubleblind crossover randomized study. Clin Neuropharmacol. 1999; 22(5):273-6.
18. Del Dotto P, Pavese N, Gambaccini G, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord. 2001;16(3): 515-20.
19. Luginger E, Wenning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2000;15(5):873-8.
20. Silva-Junior FP, Braga-Neto P, Sueli MF, de Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinson-ismRelat Disord. 2005;11(7):449-52.
21. Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000;23(2):82-5.
22. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75(1): 141-3.
23. Verhagen ML, Del Dotto P, van den MP, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 1998;50(5): 1323-6.
24. Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord. 2010 Jul 30;25(10):1357-63.
25. Evidente VG, Adler CH, Caviness JN, Gwinn-Hardy K. A pilot study on the motor effects of rimantadine in Parkinson's disease. Clin Neuropharmacol. 1999 Jan-Feb;22(1):30-2.
26. Hanagasi HA, Kaptanoglu G, Sahin HA, Emre M. The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa. Mov Disord. 2000 Sep;15(5):1016-7.
27. Rajput AH, Uitti RJ, Lang AE, Rajput A, Kumar R, Galvez-Jimenez N. Amantidine ameliorates levodopa-induced dyskinesia. Neurology. 1997;48(suppl 3):A328.
28. Rajput AH, Rajput A, Lang AE, Kumar R, Uitti RJ, Galvez-Jimenez N. New use for an old drug: amantadine benefits levodopainduced dyskinesia. Mov Disord. 1998 Sep;13(5):851.
29. Ruzicka E, Streitova H, Jech R, et al. Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease. J Neural Transm. 2000;107(11):1297-306.
30. Spieker S, Loschmann PA, Klockgether T. The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations. Mov Disord. 1999 May;14(3):517-9.
31. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999;56(11):1383-6.
32. Cohen J. Statistical power analysis for the behavioral sciences: Lawrence Erlbaum; 1988.
33. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. CochraneDatabaseSystRev. 2003(2): CD003467.
34. Martínez-Martín P, Cubo E. Scales to measure parkinsonism. Handbook of Clinical Neurology. 2007;83:289-327.
35. Goetz CG. Rating scales for dyskinesias in Parkinson's disease. Mov Disord. 1999;14(Suppl. 1):48-53.
36. Colosimo C, Martínez-Martín P, Fabbrini G, et al. Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. Mov Disord. 2010;25(9):1131-42.
37. Sweet RA, DeSensi EG, Zubenko GS. Reliability and applicability of movement disorder rating scales in the elderly. J Neuropsychiatry Clin Neurosci. 1993 Winter;5(1):56-60.